ReNeuron Group PLC (LON:RENE)

ReNeuron Group PLC (LON:RENE)


Share Price
204.70 p
Change
-0.3001 (-0.15 %)
Market Cap
£65.10 m
Proactive Investors - Run By Investors For Investors

ReNeuron Group PLC RNS Release

Share Purchases by Directors


RNS Number : 6843W
ReNeuron Group plc
18 April 2019
 

 

18 April 2019

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Share Purchases by Directors

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 18 April 2019 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by a director of the Company:

 

Name

Title

Number of Ordinary Shares purchased

Total beneficial interest in the Company's Ordinary Shares

Percentage of Company's Total Voting Rights

Professor Sir Chris Evans OBE

Non-executive Director

10,000

254,605

0.802

 

 

ENDS

ENQUIRIES:

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø , Chief Executive Officer


Michael Hunt, Chief Financial Officer

 


Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 




Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

 


Nplus1 Singer Advisory LLP

+44 (0) 20 7496 3000

Aubrey Powell, Mark Taylor (Joint Broker)


 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

 

Notification and public disclosure of transactions by persons discharging managerial

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Professor Sir Chris Evans OBE

2

Reason for the notification 

a)

Position/status 

Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Purchase of ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

2.287

10,000

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

18 April 2019

f)

Place of the transaction 

London Stock Exchange AIM Market

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGGUBWCUPBGCR

ReNeuron Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use